N/A
N=81
Racial Differences in the Natriuretic Peptide Response to Glucose Challenge
Healthy · Natriuretic Peptides · Metabolic Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT03072602 ↗Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcome: Primary: Plasma MRproANP — 23 Percentage of change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Study diet (Dietary_supplement); Glucose Challenge (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Alabama at Birmingham
- Primary completion
- Oct 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma MRproANP |
23 | — |
| SECONDARY The Difference in Circulating Plasma MRproANP |
23; 34 | — |
| SECONDARY Serum Insulin |
98.5; 69.7 | — |
| SECONDARY Serum Glucose |
129.9; 126.8 | — |
| SECONDARY Plasma NTproBNP |
-1; -3 | — |
| SECONDARY Change in Neprilysin (Membrane Metalloendopeptidase) mRNA Expression Levels Between African-Americans and Whites |
3.4; 1.0 | — |
Summary
The purpose of the study is to discover any racial dissimilarity in the response of Natriuretic peptide (NP) system to acute metabolic influences such as a high carbohydrate challenge
Eligibility Criteria
Inclusion Criteria
- Age 18-40 years
- Blood pressure less than 140/90
- Estimated creatinine clearance >60cc/min
- Willingness to comply with the study diet
Exclusion Criteria
- History of hypertension
- History of cardiovascular, renal, or liver disease
- Diabetes or use of glucose-lowering medications
- Use of vasoactive or diuretic medications
- Atrial fibrillation
- Anemia (Hematocrit 3x upper limit of normal)
- Women taking hormonal birth control
- Current smokers
- Regular users of non-steroid anti-inflammatory medications
Data sourced from ClinicalTrials.gov (NCT03072602). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.